Cardiovascular Journal of Africa: Vol 27 No 5 (September/October 2016)

57 / 70

CARDIOVASCULAR JOURNAL OF AFRICA • Volume 27, No 5, September/October 2016 AFRICA 327
11. Guize L, Thomas F, Pannier B, Bean K, Jego B, Benetos A. All-cause
mortality associated with specific combinations of the metabolic
syndrome according to recent definitions. Diabetes Care 2007; 30(9):
2381–2387.
12. Oluyombo R, Olamoyegun MA, Olaifa O, Iwuala SO, Babatunde OA.
Cardiovascular risk factors in semi-urban communities in southwest
Nigeria: Patterns and Prevalence. J Epidemiol Global Health 2014; 5(2):
167–174.
13. Akpa MR, Alasia DD, Altraide DD, Emem-Chioma PC, Wokoma IS.
Profile and outcome of medical emergencies in a tertiary health institu-
tion in Port Harcourt, Nigeria. Niger Health J 2013; 13(1): 48–53.
14. Third Report of the National Cholesterol Education Program (NCEP).
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III) Final Report.
Date
of search; 17/12/2014.
15. Bonita R, Reddy S, Galbraith, et al . Neglected global epidemics: three
growing threats. In: Beaglehole, Irwin A, Prentice T (eds). Shaping the
Future. Geneva: World Health Organization, 2003: 83–102.
16. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden
WB, et al.; On behalf of the American Heart Association Statistics
Committee and Stroke Statistics Subcommittee. Heart disease and
Stroke Statistics 2013 update: a report from the American Heart
Association. Circulation 2013; 127: e6–e245.
17. Yusuf HR, Giles WH, Croft JB, Anda RF, Casper ML. Impact of
multiple risk factor profiles on determining cardiovascular disease risk.
Prev Med 1998: 27(1): 1–9.
18. Taylor H, Liu J, Wilson G, et al. Distinct component profiles and high
risk among African Americans with metabolic syndrome: the Jackson
Heart Study. Diabetes Care 2008; 31(16): 1248–1253.
19. Steyn K, Damasceno A. Lifestyle and related risk factors for chronic
diseases. In: Jamison DT, Feachem RG, Makgoba MW, et al. (eds)
Disease and Mortality in Sub-Saharan Africa. 2nd edn. Washington DC:
World Bank, 2006; Ch 18.
20. Panniyammakal J, Dorairaj P, Shifalika G, Lakshmy R, Sandosh P, et
al. Impact of comprehensive cardiovascular risk reduction programme
on risk factor clustering associated with elevated blood pressure in an
Indian industrial population. Indian J Med Res 2012; 135: 485–493.
21. Cappucio F P, Plange-Rhule J, Philips RO, Eastwood JB. Prevention of
hypertension and stroke in Africa. Lancet 2000; 356: 677–678.
22. Eileen MS, Kathy AB, Mercy WK, Shiriki KK. Behavioural strategies
for cardiovascular risk reduction in diverse and underserved racial/
ethnic groups. Circulation 2012; 125: 171–184.
23. Pilote L, Dasgupta K, Guru V, Humphries KH, McGrath J, Norris C, et
al. A comprehensive view of sex-specific issues related to cardiovascular
disease. Can Med Assoc J 2007; 176: S1–S444.
24. Kruger J. Prevalence of regular physical activity among adults – United
States, 2001 and 2005. Morb Mortal Wkly Rep 2007; 56: 1209–1212.
25. Naci H. Comparative effectiveness of exercise and drug intervention
on mortality outcomes: meta-epidemiological study. Br Med J 2013;
347: 5577.
26. Murray CJL, Lauer JA, Hutubessy RCW, Niessen L, Tomijima N,
Rodgers A, et al. Effectiveness and costs of interventions to lower
systolic blood pressure and cholesterol: a global and regional analysis
on reduction of cardiovascular disease risk. Lancet 2003; 361: 717–725.
27. World Health Organization. Cost effectiveness and strategic planning
(WHO-CHOICE). WHO-CHOICE Interventions. Date of Search
12/11/2014. www.who.int/choice/interventions/rf_cvd/en/
28. Bayauli PM, M’Buyamba-Kayamba JJ, Lemogoun D, Thijs L, Dramaix
M, Fagard R, et al . Cardiovascular risk factors among the inhabitants
of an urban Congolese community: results of the VITARAA study. Int
J Cardiol Metab Endocrine 2014; 4: 33–38.
29. Dahiru T, Ejembi CL. Clustering of cardiovascular disease risk factors
in semi-urban population in northern Nigeria. Niger J Clin Pract 2013;
16(4): 511–516.
30. Ng M, Fleming T, Robinson M, Thomson B, Graetz N, Margono C,
Mullany EC. Global, regional, and national prevalence of overweight
and obesity in children and adults during 1980-2013: a systematic
analysis for the Global Burden of Disease Study 2013. Lancet 2014;
384(9945): 766–781.
31. Thoenes M, Bramlage P, Khan BV, Schieffer B, Kirch W, Weir MR.
Albuminuria: pathophysiology, epidemiology and clinical relevance of
an emerging marker for cardiovascular disease. Future Cardiol 2007;
3(5): 519–524.
32. Naidoo DP. The link between microalbuminuria, endothelial dysfunc-
tion and cardiovascular disease in diabetes. Cardiovasc J Sth Afr 2002;
13(4): 194–199.
33. Weir MR. Microalbuminuria and cardiovascular disease. Can J Am Soc
Nephrol 2007; 2(3): 581–590.
34. Gaede P, Pedersen O. Target intervention against multiple-risk markers
to reduce cardiovascular disease in patients with type 2 diabetes. Ann
Med 2004; 36(35): 355–366.
35. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb
C, et al. Evidence-based guideline for the management of high blood
pressure in adults. Report from the Panel Members Appointed to the
Eight Joint National Committee (JNC 8). J AmMed Assoc 2014; 311(5):
507–520.
36. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter
LM. Microalbuminuria is associated with impaired brachial artery,
flow-mediated vasodilation in elderly individuals without and with
diabetes: further evidence for a link between microalbuminuria and
endothelial dysfunction- the Hoorn Study. Kidney Int 2004; 92(Suppl):
S42–44.
37. Van Sloten TT, Henry RM, Dekker JM, Nijpels G, Unger T, Schram
MT, Stehouwer CD. Endothelial dysfunction plays a key role in increas-
ing cardiovascular risk in type 2 diabetes: the Hoorn study. Hypertension
2014; 64: 1299–1305.